Triggering Receptor Expressed on Myeloid Cells-Like Protein 2 (TREML2: A Promising Drug Target and Biomarker)

Target Name: TREML2

NCBI ID: G79865

TREML2

Triggering Receptor Expressed on Myeloid Cells-Like Protein 2 (TREML2: A Promising Drug Target and Biomarker)

Introduction

Myeloid-derived suppressor cells (MDSCs) are a subset of hematopoietic stem cells that have the ability to give rise to all hematopoietic cell types. MDSCs have been shown to play a critical role in the development and maintenance of various diseases, including cancer. TREML2 , a protein expressed in MDSCs, has been identified as a potential drug target and biomarker. In this article, we will explore the biology of TREML2 and its potential as a drug target and biomarker.

The biology of TREML2

TREML2 is a 21-kDa protein that is expressed in MDSCs. It is a member of the G protein-coupled receptor (GPCR) family and is characterized by a long extracellular domain and a short intracellular domain. The intracellular domain of TREML2 contains a putative GPCR-伪 subunit and a putative GPCR-尾 subunit. The GPCR-伪 subunit consists of an amino acid loop that is involved in the formation of a GPCR-伪 dimer, while the GPCR-尾 subunit consists of a single transmembrane region.

TREML2 is involved in several cellular processes, including cell adhesion, migration, and invasion. It has been shown to promote the migration of MDSCs towards invading particles and has been used as an experimental model for the study of cancer cell migration. In addition, TREML2 has been shown to contribute to the development of MDSCs into cancer stem cells.

TREML2 has also been shown to play a role in cell survival. It has been shown to protect MDSCs from apoptosis and to promote their survival in high-glucose environments. In addition, TREML2 has been shown to regulate cellular processes that are important for cell growth and differentiation, including the production of DNA damage repair proteins.

TREML2 as a drug target

TREML2 has been identified as a potential drug target due to its involvement in several cellular processes that are important for cancer development. One of the main targets for TREML2 is the regulation of MDSC-to-mouse colon cancer cell transformation. MDSCs have been shown to be a common source of cancer stem cells, and TREML2 has been shown to play a role in their transformation into cancer cells.

In addition, TREML2 has been shown to contribute to the development of brain metastases in cancer. MDSCs have been shown to be capable of migrating to the brain and have been implicated in the development of brain metastases in several cancers. the migration of MDSCs to the brain and has been used as a model for the study of brain metastasis.

TREML2 as a biomarker

TREML2 has also been used as a biomarker for several diseases, including cancer. MDSCs have been shown to be a common source of cancer stem cells, and TREML2 has been shown to play a role in their transformation into cancer cells. In addition, TREML2 has has been shown to be expressed in a variety of cancer types, including breast, lung, and colorectal cancer. This makes it a potential biomarker for these diseases.

In addition, TREML2 has been shown to be involved in several cellular processes that are important for cancer development. It has been shown to contribute to the development

Protein Name: Triggering Receptor Expressed On Myeloid Cells Like 2

Functions: Cell surface receptor that may play a role in the innate and adaptive immune response. Acts as a counter-receptor for CD276 and interaction with CD276 on T-cells enhances T-cell activation

The "TREML2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TREML2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets